| Q38292542 | 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells |
| Q33998290 | 15-deoxy-Delta(12,14)PGJ(2) induces diverse biological responses via PPARgamma activation in cancer cells |
| Q47845542 | 5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry |
| Q36724717 | A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer |
| Q42439583 | A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats |
| Q53545029 | Activation of PPARgamma enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes. |
| Q28580476 | Activation of Penile Proadipogenic Peroxisome Proliferator-Activated Receptor gamma with an Estrogen: Interaction with Estrogen Receptor Alpha during Postnatal Development |
| Q43832285 | Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin |
| Q40838634 | Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion |
| Q24803926 | Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease |
| Q33692555 | Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. |
| Q92134605 | Anticancer properties of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one |
| Q28269915 | Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists |
| Q44272160 | Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase |
| Q41563936 | Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms and gene-gene interaction with asthma risk in a Chinese adults population |
| Q36369124 | Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies |
| Q34680692 | Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone. |
| Q64325520 | Bicyclic eremophilane-type petasite sesquiterpenes potentiate peroxisome proliferator-activated receptor γ activator-mediated inhibition of dendritic cells |
| Q28192597 | Characterization of the adipose tissue atrophy induced by peroxisome proliferators in mice |
| Q44000084 | Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPAR gamma-dependent mechanism |
| Q35918780 | Diet, fatty acids, and regulation of genes important for heart disease |
| Q44249631 | Effects of perfluorooctane sulfonate (PFOS) exposure on markers of inflammation in female B6C3F1 mice |
| Q73223344 | Effects of peroxisome proliferators on the thymus and spleen of mice |
| Q44892162 | Fatty acid-mediated inhibition of IL-12 production by murine macrophages is independent of PPARgamma |
| Q87704839 | Fibrates and risk of cancer in tissues with high PPAR-α concentration: a nested case-control study |
| Q43764296 | Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice |
| Q78942734 | Gene expression profile after peroxisome proliferator activator receptor-gamma ligand administration in dextran sodium sulfate mice |
| Q42810116 | HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiation |
| Q44761821 | Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma |
| Q73800843 | Interleukin-4-inhibited mRNA expression in mixed rat glial and in isolated microglial cultures |
| Q44700024 | Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas |
| Q34227152 | Lipid-lowering drugs in lupus: an unexplored therapeutic intervention |
| Q42446089 | Molecular determinants of the balance between co-repressor and co-activator recruitment to the retinoic acid receptor. |
| Q36772290 | Nuclear Receptor Cofactors in PPARgamma-Mediated Adipogenesis and Adipocyte Energy Metabolism |
| Q38620031 | PPAR-gamma Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors |
| Q36676571 | PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies |
| Q43956027 | PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells |
| Q30899746 | PPARgamma: observations in the hematopoietic system |
| Q59793687 | Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue |
| Q44040699 | Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia |
| Q34568687 | Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review |
| Q40592239 | Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes |
| Q44247093 | Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis |
| Q34580424 | Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases |
| Q37079967 | Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma |
| Q28366616 | Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma |
| Q35557575 | Peroxisome proliferator-activated receptor γ (PPARγ) ligands as bifunctional regulators of cell proliferation |
| Q33780711 | Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator |
| Q35688221 | Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? |
| Q35696867 | Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure. |
| Q21245560 | Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling |
| Q40341163 | Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. |
| Q30977623 | Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes |
| Q43866773 | Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid |
| Q36795404 | Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer |
| Q44332739 | Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study |
| Q37231752 | Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. |
| Q46464268 | Rosiglitazone attenuates allergic inflammation and inhibits expression of galectin-3 in a mouse model of allergic rhinitis |
| Q54483329 | Rosiglitazone prevents graft-versus-host disease (GVHD). |
| Q42526122 | Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells |
| Q35828054 | Stress- (and diet-) related regulation of hepatic nuclear receptors and its relevance for ABC-transporter functions |
| Q24810709 | Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands |
| Q34646050 | Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer |
| Q90307176 | The Role of MicroRNAs in Muscle Tissue Development in Beef Cattle |
| Q37269942 | The molecular mechanisms of action of PPAR-γ agonists in the treatment of corneal alkali burns (Review) |
| Q28238709 | The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines |
| Q44089254 | The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidative cell death |
| Q28087571 | The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling |
| Q33975633 | The use of structure-activity relationships and markers of cell toxicity to detect non-genotoxic carcinogens |
| Q33674615 | Therapeutic Implications of PPARgamma in Human Osteosarcoma |
| Q36841072 | Thiazolidinediones in dermatology |
| Q95721208 | Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats |
| Q30847206 | YY-1224, a terpene trilactone-strengthened Ginkgo biloba, attenuates neurodegenerative changes induced by β-amyloid (1-42) or double transgenic overexpression of APP and PS1 via inhibition of cyclooxygenase-2. |
| Q53400463 | [PPARgamma and thiazolidinediones, something more than a treatment for diabetes]. |